Evolus (NASDAQ:EOLS) Sets New 52-Week Low – Here’s What Happened

Evolus, Inc. (NASDAQ:EOLS) reached a new 52-week low during trading on Tuesday . The company traded as low as $9.48 and last traded at $9.80, with a volume of 917290 shares traded. The stock had previously closed at $10.00.

Wall Street Analyst Weigh In

Several brokerages have issued reports on EOLS. HC Wainwright reiterated a “buy” rating and issued a $27.00 price objective on shares of Evolus in a research report on Thursday, November 7th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Evolus in a research report on Monday, September 16th.

Evolus Stock Performance

The stock has a market cap of $620.55 million, a price-to-earnings ratio of -10.77 and a beta of 1.32. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58. The firm has a fifty day simple moving average of $12.24 and a 200-day simple moving average of $13.76.

Hedge Funds Weigh In On Evolus

Large investors have recently made changes to their positions in the company. Quest Partners LLC bought a new stake in Evolus during the 2nd quarter worth about $43,000. Quarry LP acquired a new position in Evolus in the second quarter valued at approximately $54,000. Profund Advisors LLC acquired a new position in Evolus in the second quarter valued at approximately $130,000. Point72 Asset Management L.P. acquired a new stake in Evolus during the 3rd quarter worth $132,000. Finally, Arizona State Retirement System raised its position in shares of Evolus by 9.4% during the 2nd quarter. Arizona State Retirement System now owns 14,603 shares of the company’s stock valued at $158,000 after acquiring an additional 1,253 shares during the last quarter. Institutional investors and hedge funds own 90.69% of the company’s stock.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.